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Abstract: In 2017, more than 3 out of 100 deaths worldwide were attributed to lung cancer, making it
the deadliest malignancy [1]. In Switzerland, it is the second most frequent cancer among men and the
third most frequent among women. Every year, 4,400 individuals are diagnosed with lung cancer and
3,200 die of it [2]. A well-established risk factor is smoking. Indeed, lung cancer risk is on average 5-10
times higher among smokers compared to nonsmokers [3]. The differences in smoking habits between men
and women influenced the evolution of lung cancer incidence over the last century. Men started smoking
in large numbers already in the early 1900’s, while among women smoking became more common later
in the century. In recent years, a decrease in incidence and mortality rates in developed countries has
been observed among men but not among women [4, 5]. Today lung cancer is still more common among
men than among women (incidence ratio 1.8:1) [6]. Despite smoking’s major role in lung carcinogenesis,
approximately 10-15% of all cases occur in never-smokers. Second-hand smoke, radon gas, air pollution,
exposure to occupational agents and genetic predisposition are the main risk factors to which these cases
are attributed [7]. Late diagnosis and limited treatment reduce the chances of lung cancer survival. In
Europe, lung cancer survival five years after diagnosis was reported to be, on average, lower than 15% [8].
However, a number of factors must be taken into account in order to correctly predict the prognosis of a
lung tumour. Survival has been shown to be considerably worse among patients suffering from small cell
lung cancer (SCLC) compared to those with non-small cell histology (NSCLC) [9]. Moreover, as for other
cancers, the tumour stage at time of diagnosis weighs substantially on the treatment options and their
success. Finally, women are known to have a better survival than men and the elderly a worse prognosis
compared to younger individuals [10-12]. In the present study, we update our previously published lung
cancer survival data [13] for the period 2011-2015 and we extend estimation of survival to ten years
after diagnosis. Moreover, we present for the first time survival following lung cancer in Switzerland by
histological subgroup, UICC TNM stage and age group.
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Introduction
In 2017, more than 3 out of 100 deaths worldwide were 
attributed to lung cancer, making it the deadliest malig-
nancy [1]. In Switzerland, it is the second most frequent 
cancer among men and the third most frequent among 
women. Every year, 4,400 individuals are diagnosed with 
lung cancer and 3,200 die of it [2]. A well-established 
risk factor is smoking. Indeed, lung cancer risk is on aver-
age 5-10 times higher among smokers compared to non-
smokers [3]. The differences in smoking habits between 
men and women influenced the evolution of lung cancer 
incidence over the last century. Men started smoking in 
large numbers already in the early 1900’s, while among 
women smoking became more common later in the cen-
tury. In recent years, a decrease in incidence and mortal-
ity rates in developed countries has been observed among 
men but not among women [4, 5]. Today lung cancer is 
still more common among men than among women (in-
cidence ratio 1.8:1) [6]. Despite smoking’s major role in 
lung carcinogenesis, approximately 10-15% of all cases 
occur in never-smokers. Second-hand smoke, radon gas, 
air pollution, exposure to occupational agents and genetic 
predisposition are the main risk factors to which these 
cases are attributed [7].
Late diagnosis and limited treatment reduce the chances of 
lung cancer survival. In Europe, lung cancer survival five 
years after diagnosis was reported to be, on average, lower 
than 15% [8]. However, a number of factors must be taken 
into account in order to correctly predict the prognosis of 
a lung tumour. Survival has been shown to be considerably 
worse among patients suffering from small cell lung cancer 
(SCLC) compared to those with non-small cell histology 
(NSCLC) [9]. Moreover, as for other cancers, the tumour 
stage at time of diagnosis weighs substantially on the treat-
ment options and their success. Finally, women are known 
to have a better survival than men and the elderly a worse 
prognosis compared to younger individuals [10-12]. 
In the present study, we update our previously published 
lung cancer survival data [13] for the period 2011-2015 
and we extend estimation of survival to ten years after di-
agnosis. Moreover, we present for the first time survival 
following lung cancer in Switzerland by histological sub-
group, UICC TNM stage and age group.
Methods
Study population
Data on lung cancer cases were extracted from the ano-
nymised national cancer dataset managed by the Foun-
dation National Institute of Cancer Epidemiology and 
Registration (NICER). Data from seven Swiss cancer reg-
istries were used for the present study, namely Basel City 
and Basel Country (BS/BL), Fribourg (FR), Geneva (GE), 
Ticino (TI), Valais (VS), Vaud (VD) and Zurich (ZH), 
selected by completeness of registration coverage and of 
TNM staging information over the analysis period. Reg-
istries recorded all incident cancer cases diagnosed in their 
resident population and assessed cases’ survival through 
31 December 2015. A small proportion of living cases 
(6%) had a last available follow-up date before 31 De-
cember 2015. The life status of these cases was changed 
to lost to follow-up. The incidence date refers to the date 
of confirmation of diagnosis. Completeness of case ascer-
tainment for lung cancer has been determined in all study 
registries and found to be higher than the international 
standard of at least 90% within three years after the date 
of diagnosis [14]. We selected cases with primary malig-
nant lung cancer (C33.9 to C34.9 in ICD-O, 3rd edition) 
[15], aged 30-99 years and diagnosed 1999-2015. For BS/
BL, the diagnosis period was 1999-2012 and for FR it 
was 2006-2015. Lung cancer cases were retained even if 
preceded by a primary cancer with a different topography 
[16]. All cases diagnosed at death were excluded. Tumour 
stage was coded according to the TNM classification of 
malignant tumours [17]. On average, 23% of the cases 
did not have enough information to determine tumour 
stage. The histology codes were grouped into SCLC and 
NSCLC using the definitions and morphologies described 
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NICER
Number of cases % of cases
Overall Men  7,417
Women 
5,194
Total 
12,611 100.0
Registry
BS/BL
FR
GE
TI
VD
VS
ZH
558
529
885
956
1,362
655
2,472
388
348
647
588
970
438
1,815
946
877
1,532
1,544
2,332
1,093
4,287
7.5
7.0
12.1
12.2
18.5
8.7
34.0
Histology
SCLC
NSCLC
938
6,479
710
4,484
1,648
10,963
13.1
86.9
TNM stage
I
II
III
IV
Missing
1,376
631
1,239
2,514
1,657
1,043
358
784
1,806
1,203
2,419
989
2,023
4,320
2,860
19.2
7.8
16.0
34.3
22.7
Age group
30-54
55-64
65-74
75+
825
1,894
2,716
1,982
759
1,459
1,788
1,188
1,584
3,353
4,504
3,170
12.6
26.6
35.7
25.1
by Lewis et al. [18]. Tumours other than carcinomas were 
excluded from the analysis.
Statistical analysis
Relative survival (RS) probabilities were calculated for 
consecutive time intervals after diagnosis during which 
the hazards were assumed to remain constant. Hazards 
are known to decrease more steeply in the first year after 
diagnosis; therefore, we defined intervals with increas-
ing length (at 2, 4, 6, 9, 12, 15, 18, 24, 36, 48, 60 and 
120 months after diagnosis). RS expresses the ratio of the 
observed probability of survival of cancer cases and the 
expected survival of individuals in the general popula-
tion with same age, sex, calendar year of death and can-
ton. This allows for estimating mortality due to lung 
cancer by accounting for competing risk of death [19]. 
 Survival estimates were produced using the period ap-
proach, which provides more up-to-date values than the 
traditional cohort approach [20]. In brief, period analysis 
presents the survival experience of cases selected by a peri-
od of vital status follow-up dates, in our case 2011-2015. 
Age-standardization of RS estimates used weights, as well 
as the method for calculating 95% confidence intervals 
(95% CI), as defined by the International Cancer Survival 
Standard [21]. In the case of age-specific RS (crude RS), 
95% CI were estimated by applying the delta method to a 
transformation of the cumulative hazard [22]. 
All analyses were performed using the Stata Statistical 
Software (version 15.1).
Results
A total of 12,611 cases were included in the analysis. 
Table 1 displays the contribution of cancer registries to 
the case pool, as well as the distribution of lung cancer 
diagnoses by histology, TNM stage and age group. 
As can be seen in figure 1, survival of lung cancer patients 
steeply decreased over the course of the first year following 
the diagnosis. One-year survival amounted to 59% among 
women and 50% among men. After the first year post-di-
agnosis, the sex-specific survival curves ran in parallel and 
reached a five-year survival probability of 24% in women 
and of 19% in men. Ten years after the diagnosis, women 
had a survival of 15% and men of 11%.
Table 2 shows one-, five- and ten-year age-standardized 
relative survival stratified by histology, TNM stage and 
age at diagnosis. Survival was consistently higher among 
women, regardless of the investigated prognostic factor. 
However, poor prognosis for SCLC patients seems to be 
equally dramatic for men and women. Indeed, SCLC sur-
vival was lower than 50% in both sexes already after the 
first year and decreased to single digits after five years. 
TNM stage at diagnosis is a very informative predictor 
for lung cancer survival: stage I lung cancer patients had 
a higher than 90% survival after the first year, while stage 
IV patients experienced a survival of only 27-37% at the 
end of the same period. Tumour stage is also the factor ac-
cording to which survival varied the most between sexes. 
Finally, larger differences in survival by age group were 
observed among women, as compared among men, but 
in both sexes, the highest age group (75 and older) had a 
lower survival than younger ages.
Discussion
In this study, we provided up-to-date estimates of survival 
following lung cancer diagnosis in Switzerland. The re-
ported five-year relative survival rates of 19% in men and 
24% in women are substantially higher than the European 
average (13%) [8], although they are comparable to more 
recent estimates from neighbouring countries [23, 24] and 
the United States [25]. Lung cancer prognosis seems to be 
more favourable compared to previous years [13]: one-year 
Tab. 1. Distribution of cases by cancer registry, tumour 
histology, TNM stage and age at diagnosis.
   Schweizer Krebsbulletin  Nr. 1/2019 71
survival increased from 42-48% in 2005-
2009 to 50-59% in 2011-2015, and five-
year survival from 14-18% to 19-24%. 
Increasing survival trends have also been 
observed elsewhere in Europe [26] and are 
likely attributable to the slow, but steady 
improvement in  diagnostic tools and 
treatment options in the last decades, par-
ticularly in the areas of adjuvant therapy 
following tumour resection and redefini-
tion of therapy options for advanced neo-
plasms [27]. Furthermore, overall survival 
may have benefitted from a shift towards 
tumour histologies with more favour-
able prognosis. Survival is much higher 
for the NSCLC subtypes adenocarcinoma 
and squamous cell carcinoma, whereas for 
SCLC it is dramatically low. In France, it 
was reported that in both sexes the propor-
tion of adenocarcinoma patients signifi-
cantly increased between 2000 and 2010, 
while that of squamous cell carcinoma and 
SCLC decreased [28]. Very similar pat-
terns were observed in both national and 
regional studies in Switzerland [29, 30]. 
Difference in distribution of histologic 
Men Women
Years 
since 
diagnosis
1 5 10 1 5 10
RS 95% CI RS 95% CI RS 95% CI RS 95% CI RS 95% CI RS 95% CI
Histology
SCLC
NSCLC
39.7
51.3
[36.2, 43.2]
[49.8, 52.9]
4.1
18.3
[2.6, 5.9]
[17.1, 19.6]
3.0
10.8
[1.8, 4.9]
[9.7, 12.0]
43.0
60.7
[39.0, 46.9]
[58.9, 62.5]
5.3
24.7
[3.7, 7.3]
[23.1, 26.4]
3.8
15.5
[2.4, 5.8]
[13.9, 17.1]
TNM stage
I
II
III
IV
Missing
93.1
83.9
62.2
27.4
48.2
[90.4, 95.1]
[79.5, 87.4]
[58.9, 65.4]
[25.6, 29.3]
[44.8, 51.5]
66.1
39.6
16.5
1.2
12.7
[61.4, 70.4]
[33.7, 45.5]
[14.0, 19.3]
[0.9, 1.7]
[10.6, 15.1]
38.8
22.9
9.9
0.5
7.9
[33.6, 44.0]
[17.2, 29.1]
[7.7, 12.5]
[0.3, 0.9]
[6.2, 9.9]
97.9
90.0
70.1
36.9
55.9
[95.6, 99.0]
[84.8, 93.4]
[65.9, 73.8]
[34.6, 39.2]
[52.1, 59.5]
72.4
55.7
23.1
3.0
20.0
[67.3, 76.9]
[47.4, 63.2]
[19.4, 27.0]
[2.3, 3.9]
[17.2, 22.9]
50.2
38.2
12.6
1.4
12.9
[43.5, 56.5]
[28.5, 47.8]
[9.1, 16.7]
[0.8, 2.2]
[10.5, 15.6]
Age group
30-54
55-64
65-74
75+
56.5
55.7
52.2
37.6
[52.0, 60.7]
[52.9, 58.4]
[49.9, 54.4]
[35.2, 40.1]
20.0
20.2
16.9
9.5
[16.5, 23.8]
[18.0, 22.6]
[15.2, 18.8]
[8.0, 11.1]
14.6
12.7
9.4
4.0
[11.6, 18.0]
[10.8, 14.9]
[7.9, 11.1]
[2.8, 5.5]
68.3
63.7
59.4
44.9
[63.8, 72.5]
[60.5, 66.7]
[56.6, 62.1]
[41.5, 48.2]
28.5
24.6
23.8
11.8
[24.3, 33.0]
[21.8, 27.5]
[21.2, 26.4]
[9.7, 14.2]
21.6
16.0
14.1
5.7
[17.5, 25.9]
[13.5, 18.8]
[11.7, 16.7]
[3.9, 8.0]
Fig. 1. Relative survival curves (age-standardized estimates) with 95% 
confidence intervals by sex for the follow-up period 2011-2015. 
Male and female lung cancer cases were pooled from seven Swiss cancer 
registries.
Tab. 2. One-, five- and ten-year sex-specific relative survival estimates (in %) with 95% confidence intervals (95% CI), stratified 
by tumour histology, TNM stage and age at diagnosis. All estimates are age-standardized, except the crude, age-specific figures.
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types may also partially explain different survival expe-
riences for the two sexes. Genetic and hormonal factors 
have been associated with better prognosis of lung cancer 
among women [10]. Moreover, women seem to experience 
longer survival after both resection of early stage tumour 
and treatment for metastatic disease [10]. Finally, survival 
after lung cancer in non-smokers has been reported to be 
higher than that after lung cancer in smokers, and lung 
cancer not associated to smoking habits is much more fre-
quent among women than among men [3, 31, 32]. 
SCLC is much less common, but far deadlier than NSCLC. 
It is an aggressive tumour of neuroendocrine origin with a 
rapid doubling time and tendency to spread early to other 
organs [9]. The five-year relative survival is lower than 
5%, mainly because of the unfavourable stage distribu-
tion: in our analysis, 61% of NSCLC cases were diagnosed 
at stages III-IV, whereas SCLC stages III-IV were observed 
at diagnosis in 93% of the cases (data not shown). Regard-
less of histology, TNM stage at diagnosis is a very impor-
tant prognostic factor for lung cancer, as also the majority 
of NSCLC cases are diagnosed at advanced stages. A pa-
tient diagnosed with malignant lung cancer can expect a 
five-year survival probability that ranges from 66-72% if 
the tumour is at stage I, to 1-3% if diagnosed at stage IV. 
Early diagnosis is therefore likely to dramatically improve 
survival following lung cancer. A recently published mod-
elling study has evaluated the cost-effectiveness of a lung 
cancer screening program in Switzerland by using the re-
sults from two major screening trials. The main conclu-
sions were that screening by low-dose CT scan (LDCT) 
may be feasible in Switzerland, and that in the most cost-
effective scenario lung cancer mortality may be reduced by 
up to 15%, although the costs of the intervention would 
be considerable [33].
Survival varies less by age group than it does according to 
sex, histology and TNM stage at diagnosis. However, in 
both sexes it is noticeably lower among individuals aged 
75 or more compared to younger individuals. The worse 
survival experience of older patients may be attributed 
to a greater prevalence of comorbidities interacting with 
lung cancer, as well as to a higher treatment toxicity [11, 
12]. Tumour resection is often considered not feasible at 
higher ages, however as less invasive surgery options be-
come available, more effective treatment possibilities will 
be accessible to the elderly [34]. 
One- and five-year survival are used as a standard for 
quantifying lung cancer prognosis, as historically lung 
cancer survival has been very low already after five years 
from diagnosis. However, as survival gradually improves 
it becomes necessary to characterise cancer prognosis over 
a longer period. Indeed, in this work we observed that 
ten-year age-standardized relative survival for 2011-2015 
is as high (11-15%) as the five-year survival that was re-
ported in Switzerland for the period 1995-1999 [13]. 
In summary, in 2011-2015 lung cancer survival in 
Switzer land was higher than that reported for previous 
periods, likely because of improved diagnosis and treat-
ment, as well as because of the shift towards histologies 
with more favourable prognosis. A screening program was 
found to be potentially cost-effective in Switzerland, and 
the relevant stakeholders should evaluate its actual feasi-
bility and affordability. Despite the improvements, lung 
cancer survival is still much lower than that of other can-
cer types, which underlines the importance of pursuing 
smoking cessation, as it is an effective preventive measure 
and even provides enhanced survival experience among in-
dividuals already diagnosed with lung cancer [35]. Finally, 
as the elderly have a poorer prognosis than the rest of the 
population and represent a large group of lung cancer sur-
vivors in Switzerland, it is essential to take into account 
their specific healthcare needs.
References
1. Roth GA, et al. Global, regional, and national age-sex-specific 
mortality for 282 causes of death in 195 countries and territories, 
1980–2017: a systematic analysis for the Global Burden of Dis-
ease Study 2017. Lancet 392: 1736–1788, 2018.
2. Atlas 2018, Statistics, Cancer, Incidence, Mortality, Prevalence | 
NICER. [Online]. Available: http://www.nicer.org/en/statistics-
atlas/. [Accessed: 18-Dec-2018].
3. Ma Y and Li MD. Establishment of a Strong Link Between Smok-
ing and Cancer Pathogenesis through DNA Methylation Analy-
sis. Sci Rep 7: 1811, 2017.
4. Levi F, Lucchini F, Negri E, and La Vecchia C. The end of the 
tobacco-related lung cancer epidemic in Europe. J Natl Cancer 
Inst 95: 631–632, 2003.
5. Levi F, et al. Trends in lung cancer among young European wom-
en: The rising epidemic in France and Spain. Int J Cancer 121: 
462–465, 2007.
6. Arndt V, et al. Swiss Cancer Report 2015 - Current situation and 
developments. Neuchâtel, 2016.
7. Samet JM, et al. Lung cancer in never smokers: clinical epidemi-
ology and environmental risk factors. Clin Cancer Res 15: 5626–
5645, 2009.
8. Francisci S, et al. Survival patterns in lung and pleural cancer in 
Europe 1999–2007: Results from the EUROCARE-5 study. Eur 
J Cancer 51: 2242–2253, 2015.
9. Oronsky B, Reid TR, Oronsky A, and Carter CA. What’s New in 
SCLC? A Review. Neoplasia 19: 842–847, 2017.
10. Patel JD. Lung Cancer in Women. J Clin Oncol 23: 3212–3218, 
2005.
11. Owonikoko TK, et al. Lung Cancer in Elderly Patients: An Anal-
ysis of the Surveillance, Epidemiology, and End Results Database. 
J Clin Oncol 25: 5570–5577, 2007.
12. Pallis AG, et al. Efficacy and treatment tolerance in older patients 
with NSCLC: a meta-analysis of five phase III randomized trials 
conducted by the Hellenic Oncology Research Group. Ann Oncol 
22: 2448–2455, 2011.
13. Bordoni A, et al. Trends in Lung Cancer Survival in Switzerland. 
Swiss Cancer Bull 3: 240–244, 2012.
14. Lorez M, et al. Evaluation of completeness of case ascertainment in 
Swiss cancer registration. Eur J Cancer Prev; pp. S139–S146, Sep. 
2017.
NICER
   Schweizer Krebsbulletin  Nr. 1/2019 73
15. World Health Organization - International Agency for Research 
on Cancer, International Classification of Diseases for Oncology 
(2000). Third Edition. Geneva.
16. Rosso S, et al., Multiple tumours in survival estimates. Eur J Can-
cer 45: 1080–1094, 2009.
17. Union for International Cancer Control (UICC). TNM Classifica-
tion of Malignant Tumours, 7th ed. Geneva, 2011.
18. Lewis DR, Check DP, Caporaso NE, Travis WD, and Devesa SS. 
US lung cancer trends by histologic type. Cancer 120: 2883–
2892, 2014.
19. Ederer F, Axtell LM, and Cutler SJ. The relative survival rate: a 
statistical methodology. Natl Cancer Inst Monogr 6: 101–121, 
1961.
20. Brenner H, Gefeller O, and Hakulinen T. Period analysis for ‘up-
to-date’ cancer survival data: theory, empirical evaluation, compu-
tational realisation and applications. Eur J Cancer 40: 326–335, 
2004.
21. Corazziari I, Quinn M, and Capocaccia R. Standard cancer patient 
population for age standardising survival ratios. Eur J Cancer 40: 
2307–2316, 2004.
22. Dickman PW and Coviello E. Estimating and modeling relative 
survival. Stata J 15: 186–215, 2015.
23. STATISTIK AUSTRIA - Bundensanstalt Statistik Oesterreich. 
Luftröhre, Bronchien und Lunge (C33-C34) - Relative Über-
lebensraten in Österreich nach Geschlecht (1987-2014). [Online]. 
Available: https://www.statistik.at/web_de/statistiken/menschen_ 
und_gesellschaft/gesundheit/krebserkrankungen/luftroehre_bron-
chien_lunge/index.html. [Accessed: 28-Dec-2018].
24. Krebs in Deutschland für 2013/2014. Berlin, 2017.
25. Richards TB, et al. Lung cancer survival in the United States by 
race and stage (2001-2009): Findings from the CONCORD-2 
study. Cancer 123: 5079–5099, 2017.
26. Bordoni A, Uhry Z, Antunes L, and GRELL EUROCARE-5 
Working Group. Trends in net survival lung cancer in six Europe-
an Latin countries: results from the SUDCAN population-based 
study. Eur J Cancer Prev: S70–S76, 2017.
27. Wakelee H, Kelly K, and Edelman MJ. 50 Years of progress in the 
systemic therapy of non-small cell lung cancer. Am Soc Clin On-
col Educ Book Am Soc Clin Oncol Annu Meet: 177–189, 2014.
28. Locher C, et al. Major changes in lung cancer over the last ten 
years in France: the KBP-CPHG studies. Lung Cancer 81: 32–38, 
2013.
29. Lorez M, Rohrmann S, Heusser R, Arndt V, and the NICER 
Working Group. Lung Cancer Trends by Histologic Subtype in 
Switzerland. Swiss Cancer Bull 37: 179–185, 2017.
30. Oberli LS, Valeri F, Korol D, Rohrmann S, and Dehler S. 31 years 
of lung cancer in the canton of Zurich, Switzerland: incidence 
trends by sex, histology and laterality. Swiss Med Wkly 146: 
w14327, 2016.
31. Subramanian J and Govindan R. Lung Cancer in Never Smokers: 
A Review. J Clin Oncol 25: 561–570, 2007.
32. Nordquist LT, Simon GR, Cantor A, Alberts WM, and Bepler 
G. Improved survival in never-smokers vs current smokers with 
primary adenocarcinoma of the lung. Chest 126: 347–351, 2004.
33. Tomonaga Y, et al. Cost-effectiveness of low-dose CT screening 
for lung cancer in a European country with high prevalence of 
smoking—A modelling study. Lung Cancer 121: 61–69, 2018.
34. Tsao AS, et al. Scientific Advances in Lung Cancer 2015. J Thorac 
Oncol 11: 613–638, 2016.
35. Tanner NT, et al. The Association between Smoking Abstinence 
and Mortality in the National Lung Screening Trial. Am J Respir 
Crit Care Med 193: 534–541, 2016.
For additional information on cancer in Switzerland, see 
the NICER website at http://nicer.org/
§Members of the NICER Working Group for these analyses: Basel – K. 
Staehelin; Fribourg – C. Egger-Hayoz; Geneva – C. Bouchardy; Ticino 
– A. Bordoni; Valais – I. Konzelmann; Vaud – R. Blanc-Moya & J.L. 
Bulliard; Zuerich & Zug – S. Rohrmann.
NICER
Correspondence:
Francesco Galli, MSc, Research Associate
National Institute for Cancer Epidemiology  
and Registration (NICER)
c/o University of Zurich
Hirschengraben 82, CH-8001 Zurich
francesco.galli@nicer.org 
